DELCATH SYSTEMS TO HOST CONFERENCE CALL TO PROVIDE CORPORATE UPDATE

New York - February 13, 2008 -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Company will host a conference call to provide a corporate update. Richard Taney, President and Chief Executive Officer of Delcath Systems, will host the call beginning at 4:30 P.M. Eastern Time on Wednesday, February 27, 2008. A question and answer session will immediately follow management's prepared remarks.

The conference call will be webcast live and may be accessed by visiting Delcath Systems' website at www.delcath.com. A replay of the audio webcast will be available on the Company's website starting shortly after the call on February 27, 2008.

Those parties interested in participating in the live call may join by dialing (800) 762-9058 in the U.S. and referencing conference identification number 3845399. A telephone replay of the conference call will be available shortly after the conclusion of the live call and can be accessed by dialing (800) 406-7325 in the U.S and referencing conference identification number 3845399. The replay will be available until the end of the day on Friday, March 28, 2008.

About Delcath Systems, Inc.
Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested in Phase III and Phase II clinical trials for the treatment of hepatocellular carcinoma and metastatic tumors in the liver, including melanomas, neuroendocrine tumors and adenocarcinomas. The Company's intellectual property portfolio currently consists of 28 patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.